Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1990;32(2):88-94.
doi: 10.1007/BF01754204.

Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice

T Itoh  1 , Y Sakata, Y Yoshida, K Tsushima, H Suzuki, S Saitoh, Y Tamura, H Ogasawara, N Sugimoto, H Takemori
Affiliations
Comparative Study

Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice

T Itoh et al. Cancer Immunol Immunother. 1990.

Abstract

We have previously reported that the combination of murine recombinant interferon beta (Mu-rIFN beta) with murine recombinant interferon gamma (Mu-rIFN gamma) provided greater inhibition of tumor growth than did each one alone in MethA-bearing mice. In the present study the effect of addition of human recombinant interleukin-2 (Hu-rIL-2) to the combination of Mu-rIFN beta with Mu-rIFN gamma on tumor growth in BALB/c mice bearing syngeneic MethA fibrosarcoma was examined. Low doses of Hu-rIL-2 (5 x 10(3) U or 5 x 10(4) U at 3-day intervals) showed no antitumor activity, while a high dose of Hu-rIL-2 (5 x 10(5) U) showed profound growth inhibition. The administration of IL-2 (ranging between 5 x 10(3) U and 5 x 10(5) U) in addition to the combination of IFN beta and IFN gamma showed more augmented antitumor effects in a dose-dependent manner. Furthermore, the simultaneous administration of IL-2, IFN beta and IFN gamma had more effective therapeutic activity, compared with the sequential administration of interferons and IL-2. These findings indicated that IL-2 in combination with IFN beta and gamma was effective for cancer treatment.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Agah R, Malloy B, Sherrod A, Mazumder A. Successful therapy of natural killer-resistant pulmonary metastases by the synergism of β-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res. 1988;48:2245. - PubMed
    1. Aguet M, Belardelli F, Blanchard B, Marcucci F, Gresser I. High-affinity binding of125I-labeled mouse interferon to a specific cell surface receptor. IV. Mouse interferon and cholera toxin do not complete for the common receptor site of α/β interferon. Virology. 1982;117:541. - PubMed
    1. Branca AA, Baglioni C. Evidence that types I and II interferons have different receptors. Nature. 1981;294:768. - PubMed
    1. Brysk MM, Tschen EH, Hudson RD, Smith EB, Fleischmann WR, Jr, Black HS. The activity of interferon on ultraviolet light-induced squamous cell carcinomas in mice. J Am Acad Dermatol. 1981;5:61. - PubMed
    1. Cheever MA, Greenberg PD, Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin 2. J Immunol. 1981;126:1318. - PubMed

Publication types

MeSH terms

LinkOut - more resources